# Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients

> **NCT01092754** · PHASE4 · COMPLETED · sponsor: **Guerbet** · enrollment: 100 (actual)

## Conditions studied

- Pathological Processes

## Interventions

- **PROCEDURE:** MRI
- **PROCEDURE:** MRI
- **DRUG:** Gadoversetamide

## Key facts

- **NCT ID:** NCT01092754
- **Lead sponsor:** Guerbet
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2003-12
- **Final completion:** 2003-12
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2017-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01092754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01092754, "Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patients". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT01092754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*